Medprin Regenerative Medical Technologies Co., Ltd. (SHE:301033)
China · Delayed Price · Currency is CNY 46.94
-0.37 (-0.78%)
Jun 10, 2026, 4:00 PM EDT
SHE:301033 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 365.88 | 361.22 | 272.26 | 227.54 | 195.02 | 153.79 |
Other Revenue | 7.61 | 7.61 | 6.18 | 3.33 | 0.24 | - |
| 373.49 | 368.83 | 278.44 | 230.87 | 195.25 | 153.79 | |
Revenue Growth (YoY) | 26.63% | 32.46% | 20.61% | 18.24% | 26.96% | 24.51% |
Cost of Revenue | 78.09 | 75.81 | 57.77 | 41.58 | 31.26 | 27.29 |
Gross Profit | 295.4 | 293.02 | 220.67 | 189.29 | 163.99 | 126.5 |
Selling, General & Admin | 143.4 | 139.42 | 114.04 | 116.17 | 105.57 | 73 |
Research & Development | 37.72 | 36.76 | 26.95 | 26.78 | 30.61 | 25.88 |
Other Operating Expenses | 0.81 | 0.42 | 0.62 | 2.1 | 2.04 | 0.66 |
Operating Expenses | 181.86 | 176.55 | 141.7 | 145.09 | 138.25 | 99.49 |
Operating Income | 113.54 | 116.47 | 78.97 | 44.2 | 25.74 | 27.01 |
Interest Expense | -0.01 | -0.02 | -0.9 | -2.21 | -1.78 | -0.49 |
Interest & Investment Income | 3.73 | 4.52 | 5.48 | 5.45 | 9.78 | 6.49 |
Currency Exchange Gain (Loss) | -0.44 | -0.44 | 0.44 | -0.01 | 1.04 | -0.47 |
Other Non Operating Income (Expenses) | -1.73 | -0.54 | -0.26 | -0.2 | -0.13 | -0.14 |
EBT Excluding Unusual Items | 115.08 | 119.99 | 83.72 | 47.24 | 34.65 | 32.4 |
Gain (Loss) on Sale of Investments | 1.01 | 0.19 | 0.15 | 0.13 | -0.81 | 0.98 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0 | - | 0.17 | 0.01 |
Asset Writedown | -3.17 | -2.7 | -0.48 | -0.22 | -1.29 | -0.07 |
Other Unusual Items | 8.69 | 8.69 | 9.77 | 0.87 | 7.25 | 18.28 |
Pretax Income | 121.62 | 126.17 | 93.16 | 48.02 | 39.96 | 51.6 |
Income Tax Expense | 11.94 | 13.04 | 14.3 | 7.14 | 4.23 | 6.92 |
Earnings From Continuing Operations | 109.68 | 113.13 | 78.85 | 40.88 | 35.73 | 44.68 |
Minority Interest in Earnings | - | - | - | - | 0.16 | 0.03 |
Net Income | 109.68 | 113.13 | 78.85 | 40.88 | 35.89 | 44.71 |
Net Income to Common | 109.68 | 113.13 | 78.85 | 40.88 | 35.89 | 44.71 |
Net Income Growth | 24.54% | 43.46% | 92.90% | 13.89% | -19.73% | 20.95% |
Shares Outstanding (Basic) | 67 | 66 | 66 | 66 | 66 | 57 |
Shares Outstanding (Diluted) | 67 | 67 | 66 | 66 | 66 | 57 |
Shares Change (YoY) | 0.94% | 1.87% | -0.33% | -0.80% | 17.43% | 14.83% |
EPS (Basic) | 1.65 | 1.71 | 1.20 | 0.62 | 0.54 | 0.79 |
EPS (Diluted) | 1.64 | 1.69 | 1.20 | 0.62 | 0.54 | 0.79 |
EPS Growth | 23.38% | 40.83% | 93.55% | 14.82% | -31.65% | 5.33% |
Free Cash Flow | 86.63 | 116.05 | 83.22 | 67.6 | -87.65 | -86.2 |
Free Cash Flow Per Share | 1.30 | 1.73 | 1.27 | 1.02 | -1.32 | -1.52 |
Dividend Per Share | 0.700 | 0.700 | 0.600 | 0.400 | 0.200 | 0.100 |
Dividend Growth | 16.67% | 16.67% | 50.00% | 100.00% | 100.00% | - |
Gross Margin | 79.09% | 79.45% | 79.25% | 81.99% | 83.99% | 82.25% |
Operating Margin | 30.40% | 31.58% | 28.36% | 19.15% | 13.18% | 17.56% |
Profit Margin | 29.37% | 30.67% | 28.32% | 17.71% | 18.38% | 29.08% |
Free Cash Flow Margin | 23.20% | 31.46% | 29.89% | 29.28% | -44.89% | -56.05% |
EBITDA | 139.95 | 142.74 | 104.67 | 68.11 | 38.99 | 33.18 |
EBITDA Margin | 37.47% | 38.70% | 37.59% | 29.50% | 19.97% | 21.57% |
D&A For EBITDA | 26.41 | 26.27 | 25.7 | 23.91 | 13.25 | 6.17 |
EBIT | 113.54 | 116.47 | 78.97 | 44.2 | 25.74 | 27.01 |
EBIT Margin | 30.40% | 31.58% | 28.36% | 19.15% | 13.18% | 17.56% |
Effective Tax Rate | 9.82% | 10.34% | 15.35% | 14.88% | 10.58% | 13.41% |
Revenue as Reported | 373.49 | 368.83 | 278.44 | 230.87 | 195.25 | 153.79 |
Advertising Expenses | - | 16.02 | 19.07 | 32.56 | 43.12 | 23.01 |